Subject
Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery
Reference36 articles.
1. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype;Mitra;Br J Cancer,2008
2. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer;Castro;J Clin Oncol,2013
3. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death;Na;Eur Urol,2017
4. Center for Drug Evaluation and Research. FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer.
5. Center for Drug Evaluation and Research. FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer. https://www.fda.gov/drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献